Thrombotic vs. Bleeding Events of Interruption of Dual Antiplatelet Therapy within 12 Months among Patients with Stent-Driven High Ischemic Risk Definition following PCI

Table 4

Primary ischemic endpoint in selected subgroups.

	DAPT interruption ≤12 months (n = 1122)	DAPT maintenance >12 months (n = 2809)	HR (95% CI)	for interaction
Age				0.570
<65 years	21/765 (2.7%)	34/1983 (1.7%)	1.688 (0.979–2.912)
≥65 years	24/358 (6.7%)	27/825 (3.3%)	2.168 (1.250–3.762)
Sex				0.470
Female	12/268 (4.5%)	12/654 (1.8%)	2.454 (1.102–5.466)
Male	33/855 (3.9%)	49/2154 (2.3%)	1.829 (1.175–2.849)
Diabetes mellitus				0.350
No	20/578 (3.5%)	33/1499 (2.2%)	1.596 (0.914–2.786)
Yes	25/545 (4.6%)	28/1309 (2.1%)	2.346 (1.365–4.034)
Chronic kidney disease				0.834
No	35/1019 (3.4%)	47/2560 (1.8%)	2.026 (1.306–3.142)
Yes	10/104 (9.6%)	14/248 (5.6%)	1.751 (0.778–3.943)
Smoking				0.182
No	24/495 (4.8%)	24/1208 (2.0%)	2.577 (1.462–4.542)
Yes	21/628 (3.3%)	37/1600 (2.3%)	1.545 (0.903–2.644)
Acute coronary syndrome				0.310
No	18/446 (4.0%)	22/1240 (1.8%)	2.479 (1.326–4.635)
Yes	27/677 (4.0%)	39/1568 (2.5%)	1.632 (0.996–2.673)
Previous MI				0.440
No	31/882 (4.0%)	46/2202 (2.1%)	1.767 (1.120–2.788)
Yes	14/241 (5.8%)	15/606 (2.5%)	2.531 (1.212–5.287)
Multivessel disease				0.284
No	6/125 (4.8%)	4/283 (1.4%)	3.683 (1.037–13.083)
Yes	39/998 (3.9%)	57/2525 (2.3%)	1.813 (1.206–2.728)
Generation of DES				0.889
First-generation DES	4/115 (3.5%)	6/286 (2.1%)	2.030 (0.562–7.340)
Second-generation DES	41/1008 (4.1%)	55/2522 (2.2%)	1.965 (1.310–2.946)
ARC-HBR				0.699
No	24/858 (2.8%)	39/2236 (1.7%)	1.695 (1.018–2.823)
Yes	20/264 (7.6%)	23/573 (4.0%)	1.977 (1.085–3.602)

DES indicates drug-eluting stent.